Serum Institute of India seeks govt's nod to manufacture cervical cancer vaccine
The Serum Institute of India (SII) has sought the government’s approval to manufacture its indigenously developed quadrivalent human papillomavirus (qHPV) vaccine against cervical cancer, after the completion of Phase II/III clinical trials in order to ensure its early availability in the country.
The vaccine maker is to seek market authorization as well as a manufacturing licence from the Drugs Controller General of India (DCGI) for the vaccine.
India has the second-highest death rate due to cervical cancer, and HPV is its most common cause.
If the government approves the company's proposal, it would only be a matter of time before the indigenously developed qHPV vaccine would be introduced in India's Universal Immunization Program.
Gardasil and Cervarix current treatment options
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze